$ENLV
Enlivex Therapeutics Ltd. Stock $enlv

$enlv Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 20-F Financial Statement

#000121390024037878 Filed on April 30, 2024

Income Statement

Concept	2023 Q4	2023	2022 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.639M	$6.139M	$2.145M
YoY Change	-23.59%	-13.58%	-19.0%
% of Gross Profit
Research & Development	$4.452M	$18.21M	$5.700M
YoY Change	-21.89%	-2.58%	10.34%
% of Gross Profit
Depreciation & Amortization	$200.0K	$835.0K	$221.0K
YoY Change	-9.5%	7.46%	47.33%
% of Gross Profit
Operating Expenses	$6.091M	$25.15M	$7.845M
YoY Change	-22.36%	-2.5%	0.4%
Operating Profit		-$29.40M
YoY Change		13.95%
Interest Expense	$327.0K	$327.0K	$0.00
YoY Change		-106.23%
% of Operating Profit
Other Income/Expense, Net	$913.0K	$327.0K	$656.0K
YoY Change	39.18%	-53.75%	-78.69%
Pretax Income	-$9.095M	-$29.07M	-$7.189M
YoY Change	26.51%	-6.41%	51.79%
Income Tax
% Of Pretax Income
Net Earnings	-$9.095M	-$29.07M	-$7.189M
YoY Change	26.51%	-6.41%	51.79%
Net Earnings / Revenue
Basic Earnings Per Share		-$1.56
Diluted Earnings Per Share	-$0.49	-$1.57	-$0.39
COMMON SHARES
Basic Shares Outstanding	18.60M shares	18.57M shares	18.42M shares
Diluted Shares Outstanding		18.57M shares

Balance Sheet

Concept	2023 Q4	2023	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$27.32M	$27.32M	$50.24M
YoY Change	-45.63%	-45.63%	-40.28%
Cash & Equivalents	$813.0K	$813.0K	$49.95M
Short-Term Investments	$26.51M	$26.51M	$299.0K
Other Short-Term Assets	$6.444M	$6.444M	$2.086M
YoY Change	208.92%	208.92%	-9.78%
Inventory
Prepaid Expenses	$1.107M		$2.086M
Receivables
Other Receivables	$113.0K		$125.0K
Total Short-Term Assets	$33.76M	$33.76M	$52.33M
YoY Change	-35.48%	-35.48%	-39.46%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.539M	$1.539M	$9.875M
YoY Change	-84.42%	-89.67%	20.15%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.528M	$1.528M	$412.0K
YoY Change	270.87%	270.87%	-15.05%
Total Long-Term Assets	$3.067M	$3.067M	$15.31M
YoY Change	-79.97%	-79.97%	75.92%
TOTAL ASSETS
Total Short-Term Assets	$33.76M	$33.76M	$52.33M
Total Long-Term Assets	$3.067M	$3.067M	$15.31M
Total Assets	$36.83M	$36.83M	$67.64M
YoY Change	-45.55%	-45.55%	-28.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$827.0K	$827.0K	$1.948M
YoY Change	-57.55%	-57.55%	121.87%
Accrued Expenses	$4.001M	$4.001M	$4.659M
YoY Change	-14.12%	-14.12%	25.01%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$0.00
YoY Change
Total Short-Term Liabilities	$6.061M	$6.061M	$6.607M
YoY Change	-8.26%	-8.26%	40.04%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$686.0K	$686.0K	$4.194M
YoY Change	-83.64%	-83.64%	-22.17%
Total Long-Term Liabilities	$686.0K	$686.0K	$4.194M
YoY Change	-83.64%	-83.64%	-22.17%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.061M	$6.061M	$6.607M
Total Long-Term Liabilities	$686.0K	$686.0K	$4.194M
Total Liabilities	$6.747M	$6.747M	$10.80M
YoY Change	-37.53%	-37.53%	6.87%
SHAREHOLDERS EQUITY
Retained Earnings	-$112.1M		-$83.03M
YoY Change	35.02%		59.77%
Common Stock	$2.137M		$2.117M
YoY Change	0.94%		0.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$30.08M	$30.08M	$56.84M
YoY Change
Total Liabilities & Shareholders Equity	$36.83M	$36.83M	$67.64M
YoY Change	-45.55%	-45.55%	-28.91%

Cashflow Statement

Concept	2023 Q4	2023	2022 Q4
OPERATING ACTIVITIES
Net Income	-$9.095M	-$29.07M	-$7.189M
YoY Change	26.51%	-6.41%	51.79%
Depreciation, Depletion And Amortization	$200.0K	$835.0K	$221.0K
YoY Change	-9.5%	7.46%	47.33%
Cash From Operating Activities	-$5.277M	-$23.52M	-$4.818M
YoY Change	9.53%	-1.8%	-26.9%
INVESTING ACTIVITIES
Capital Expenditures	$7.000K	$236.0K	$2.581M
YoY Change	-99.73%	-97.09%	-349.85%
Acquisitions
YoY Change
Other Investing Activities	$4.142M	-$25.73M	-$295.0K
YoY Change	-1504.07%	-136.42%	-93.16%
Cash From Investing Activities	$4.135M	-$25.97M	-$2.876M
YoY Change	-243.78%	-141.53%	-46.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$360.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	360.0K	0.000
YoY Change		140.0%	-100.0%
NET CHANGE
Cash From Operating Activities	-5.277M	-23.52M	-4.818M
Cash From Investing Activities	4.135M	-25.97M	-2.876M
Cash From Financing Activities	0.000	360.0K	0.000
Net Change In Cash	-1.142M	-49.13M	-7.694M
YoY Change	-85.16%	-226.88%	-35.56%
FREE CASH FLOW
Cash From Operating Activities	-$5.277M	-$23.52M	-$4.818M
Capital Expenditures	$7.000K	$236.0K	$2.581M
Free Cash Flow	-$5.284M	-$23.76M	-$7.399M
YoY Change	-28.58%	-25.93%	33.12%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	us-gaap	Revenues Revenues		usd
CY2022	us-gaap	Revenues Revenues		usd
CY2023	dei	Document Type DocumentType	20-F
CY2023	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-36578
CY2023	dei	Entity Registrant Name EntityRegistrantName	Enlivex Therapeutics Ltd.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L3
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	14 Einstein Street
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Ness Ziona
CY2023	dei	Entity Address Country EntityAddressCountry	IL
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	7403618
CY2023	dei	Security12b Title Security12bTitle	Ordinary Shares, par value NIS 0.40 per share
CY2023	dei	Trading Symbol TradingSymbol	ENLV
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	18598555	shares
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023	dei	Auditor Firm AuditorFirmId	1024
CY2023	dei	Auditor Name AuditorName	Yarel + Partners
CY2023	dei	Auditor Location AuditorLocation	Tel-Aviv, Israel
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	813000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	49945000	usd
CY2023Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	26507000	usd
CY2022Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	299000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1336000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2086000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	5108000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	33764000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	52330000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1539000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9875000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1528000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5437000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	3067000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	15312000	usd
CY2023Q4	us-gaap	Assets Assets	36831000	usd
CY2022Q4	us-gaap	Assets Assets	67642000	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	827000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1948000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4001000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4659000	usd
CY2023Q4	enlv	Liability Held For Sale Current LiabilityHeldForSaleCurrent	1233000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6061000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6607000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	686000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4194000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	686000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4194000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	6747000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	10801000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.4
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.4
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	45000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	45000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18598555	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18598555	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18421852	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18421852	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2137000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2117000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	138939000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	136648000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	1101000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	1101000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-112093000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-83025000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	30084000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	56841000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	36831000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	67642000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19012000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18693000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12881000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6139000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7104000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6407000	usd
CY2023	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	-4244000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	29395000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	25797000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	19288000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-29395000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-25797000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-19288000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	327000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5263000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4820000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-29068000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-31060000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-14468000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	124000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	124000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29068000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-31060000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14344000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.56
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.69
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.81
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18574484	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18394886	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17859713	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	35487000	usd
CY2021	enlv	Cash Consideration CashConsideration	57629000	usd
CY2021	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	4455000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	53174000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	106000	usd
CY2021	enlv	Exercise Of Warrants ExerciseOfWarrants	7702000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2914000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	124000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-14468000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	85039000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	150000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2712000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-31060000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	56841000	usd
CY2023	enlv	Cash Consideration CashConsideration	513000	usd
CY2023	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	153000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	360000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1951000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-29068000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	30084000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-29068000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-31060000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-14468000	usd
CY2023	us-gaap	Depreciation Depreciation	835000	usd
CY2022	us-gaap	Depreciation Depreciation	777000	usd
CY2021	us-gaap	Depreciation Depreciation	546000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	20000	usd
CY2023	enlv	Gain Loss On Marketable Securities And Shortterm Bank Deposits GainLossOnMarketableSecuritiesAndShorttermBankDeposits	343000	usd
CY2022	enlv	Gain Loss On Marketable Securities And Shortterm Bank Deposits GainLossOnMarketableSecuritiesAndShorttermBankDeposits	-1983000	usd
CY2021	enlv	Gain Loss On Marketable Securities And Shortterm Bank Deposits GainLossOnMarketableSecuritiesAndShorttermBankDeposits	5590000	usd
CY2023	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	-4244000	usd
CY2023	enlv	Noncash Operating Lease Expense NoncashOperatingLeaseExpense	696000	usd
CY2022	enlv	Noncash Operating Lease Expense NoncashOperatingLeaseExpense	831000	usd
CY2021	enlv	Noncash Operating Lease Expense NoncashOperatingLeaseExpense	413000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1951000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2712000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2914000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-608000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-278000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1249000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-1121000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1168000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	442000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-350000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	684000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-466000	usd
CY2023	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-101000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-854000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1326000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-84000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23523000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23953000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17542000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	236000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8122000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1625000	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	133000	usd
CY2023	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	26166000	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	299000	usd
CY2023	enlv	Investment In Shortterm Bank Deposits InvestmentInShorttermBankDeposits	301000	usd
CY2022	enlv	Investment In Shortterm Bank Deposits InvestmentInShorttermBankDeposits	10004000	usd
CY2021	enlv	Investment In Shortterm Bank Deposits InvestmentInShorttermBankDeposits	20030000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1608000	usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	104417000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	62549000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	47604000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-25968000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	62524000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-38408000	usd
CY2023	enlv	Proceeds From Issuance Of Shares And Warrants Net ProceedsFromIssuanceOfSharesAndWarrantsNet	360000	usd
CY2021	enlv	Proceeds From Issuance Of Shares And Warrants Net ProceedsFromIssuanceOfSharesAndWarrantsNet	53174000	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	7702000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	150000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	106000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	360000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	150000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	60982000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-49131000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	38721000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	5032000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50357000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11636000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7012000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-408000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1226000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50357000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11636000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	1565000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	835000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	120000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.4
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-112100000	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-1983000	usd
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	5590000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><b><i>Use of estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions, it also requires that management exercise its judgment in applying the Company’s accounting policies. The Company’s management believes that the estimates, judgments and assumptions used were reasonable based upon information available at the time they were made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts in the statements of operations during each reporting period. Actual results could differ materially from those estimates.</p>
CY2023Q4	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	3.627	pure
CY2022Q4	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	3.519	pure
CY2021Q4	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	3.11	pure
CY2023	enlv	Foreign Currency Exchange Rate Increasedecrease During The Year ForeignCurrencyExchangeRateIncreasedecreaseDuringTheYear	0.03069	pure
CY2022	enlv	Foreign Currency Exchange Rate Increasedecrease During The Year ForeignCurrencyExchangeRateIncreasedecreaseDuringTheYear	0.1315	pure
CY2021	enlv	Foreign Currency Exchange Rate Increasedecrease During The Year ForeignCurrencyExchangeRateIncreasedecreaseDuringTheYear	-0.0327	pure
CY2023	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	0	usd
CY2023	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	-4244000	usd
CY2023	enlv	Patents Relatedcosts PatentsRelatedcosts	391000	usd
CY2022	enlv	Patents Relatedcosts PatentsRelatedcosts	536000	usd
CY2021	enlv	Patents Relatedcosts PatentsRelatedcosts	373000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	605000	usd
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	29068000	usd
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	31060000	usd
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	14468000	usd
CY2023	enlv	Number Of Common Shares At The Beginning Of The Year NumberOfCommonSharesAtTheBeginningOfTheYear	18421852	shares
CY2022	enlv	Number Of Common Shares At The Beginning Of The Year NumberOfCommonSharesAtTheBeginningOfTheYear	18331507	shares
CY2021	enlv	Number Of Common Shares At The Beginning Of The Year NumberOfCommonSharesAtTheBeginningOfTheYear	14587934	shares
CY2023	enlv	Weighted Average Number Of Shares Issued For Cash WeightedAverageNumberOfSharesIssuedForCash	110249	shares
CY2021	enlv	Weighted Average Number Of Shares Issued For Cash WeightedAverageNumberOfSharesIssuedForCash	2485245	shares
CY2022	enlv	Weighted Average Number Of Stock Options Exercisedin Shares WeightedAverageNumberOfStockOptionsExercisedinShares	13015	shares
CY2021	enlv	Weighted Average Number Of Stock Options Exercisedin Shares WeightedAverageNumberOfStockOptionsExercisedinShares	16715	shares
CY2023	enlv	Weighted Average Number Of Restricted Stock Units Vested WeightedAverageNumberOfRestrictedStockUnitsVested	42383	shares
CY2022	enlv	Weighted Average Number Of Restricted Stock Units Vested WeightedAverageNumberOfRestrictedStockUnitsVested	50364	shares
CY2021	enlv	Weighted Average Number Of Warrants Exercised WeightedAverageNumberOfWarrantsExercised	769819	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18574484	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18394886	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17859713	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.56
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.69
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.81
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><b><i>Concentrations of credit risk:</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents, restricted cash and bank deposits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Cash and cash equivalents, restricted cash and deposits are invested in major banks in Israel. Such deposits in Israel are not insured. Management believes that the financial institutions that hold the Company’s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company had no foreign exchange contracts or any other hedging arrangements as of December 31, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p>
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Reclassification </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Certain comparative figures have been reclassified to conform to the current year presentation. Such reclassifications did not have any significant impact on the Company’s equity, net income or cash flows.</p>
CY2023Q4	us-gaap	Cash Cash	813000	usd
CY2022Q4	us-gaap	Cash Cash	2123000	usd
CY2022	srt	Short Term Investments Other Average Yield ShortTermInvestmentsOtherAverageYield	0.0395	pure
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	47822000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	813000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	49945000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	113000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	113000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	300000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	299000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1226000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	50357000	usd
CY2023Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	26507000	usd
CY2022Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	299000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1107000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1439000	usd
CY2023Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	116000	usd
CY2022Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	522000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	113000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	125000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1336000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2086000	usd
CY2023Q4	enlv	Leasehold Improvements Cost LeaseholdImprovementsCost	8669000	usd
CY2022Q4	enlv	Leasehold Improvements Cost LeaseholdImprovementsCost	8606000	usd
CY2023Q4	enlv	Assets Classified As Held For Sale AssetsClassifiedAsHeldForSale	-7624000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4409000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11982000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2870000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2107000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1539000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9875000	usd
CY2023	us-gaap	Depreciation Depreciation	835000	usd
CY2022	us-gaap	Depreciation Depreciation	777000	usd
CY2021	us-gaap	Depreciation Depreciation	546000	usd
CY2021Q2	enlv	Grant Total Amount GrantTotalAmount	1200000	usd
CY2021Q4	enlv	Commercial Transaction CommercialTransaction	20000000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	300000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	299000	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	8000	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	8000	usd
CY2023Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	179000	usd
CY2022Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	105000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1041000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5025000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1528000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5437000	usd
CY2019Q3	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P24M
CY2019Q3	us-gaap	Area Of Land AreaOfLand	55	sqm
CY2021Q3	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P24M
CY2018Q3	us-gaap	Area Of Land AreaOfLand	420	sqm
CY2018Q3	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2023-08-31
CY2018Q3	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P60M
CY2020Q4	us-gaap	Area Of Land AreaOfLand	421	sqm
CY2020Q4	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2025-09-30
CY2020Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P33M
CY2021Q3	us-gaap	Area Of Land AreaOfLand	455	sqm
CY2021Q3	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P63M
CY2021Q3	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2026-10-31
CY2021Q3	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P22M
CY2021Q3	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2026-09-18
CY2021Q3	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P60M
CY2023	enlv	Agreement Description AgreementDescription	On September 7, 2018 the Company entered into an agreement with its Executive Chairman. Pursuant to the agreement, upon termination of the Chairman’s board service, under certain conditions defined in the agreement, the Executive Chairman will be entitled to receive an amount of up to three times his then annual base retainer plus the value of accrued benefits. As of December 31, 2023, no termination liability was accrued or payable.
CY2021Q4	enlv	Percentage Of Gross Proceeds PercentageOfGrossProceeds	0.0333	pure
CY2023	enlv	Lease Agreements Period LeaseAgreementsPeriod	P36M
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	863000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	1037000	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	698000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	766000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	875000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	449000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	689000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	179000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	5446000	usd
CY2023Q4	enlv	Rightof Use Assets Gross RightofUseAssetsGross	2161000	usd
CY2022Q4	enlv	Rightof Use Assets Gross RightofUseAssetsGross	6445000	usd
CY2023Q4	enlv	Accumulated Amortization AccumulatedAmortization	1120000	usd
CY2022Q4	enlv	Accumulated Amortization AccumulatedAmortization	1420000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1041000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5025000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	346000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	653000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	686000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4194000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1032000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4847000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y7M6D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.067	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.034	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	410000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	359000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	216000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	121000	usd
CY2023Q4	enlv	Lessee Operating Lease Liability Payments Due Year Five And Thereafter LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter	91000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1197000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	165000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1032000	usd
CY2023	enlv	Royalties In Sales Percentage RoyaltiesInSalesPercentage	1	pure
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Contingent Liability BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability	9600000	usd
CY2022Q1	us-gaap	Other General Expense OtherGeneralExpense	4800000	usd
CY2022Q2	us-gaap	Costs And Expenses CostsAndExpenses	1000000	usd
CY2023Q3	enlv	Aggregate Amount Of Ordinary Shares AggregateAmountOfOrdinaryShares	1500000	usd
CY2022Q4	enlv	Aggregate Offering Price AggregateOfferingPrice	100000000	usd
CY2022Q4	us-gaap	Debt Instrument Redemption Price Percentage DebtInstrumentRedemptionPricePercentage	0.03	pure
CY2023	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	124171	shares
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	513000	usd
CY2023	enlv	Average Gross Price Per AverageGrossPricePer	4.11
CY2023Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	153000	usd
CY2021Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	2296107	shares
CY2021Q1	enlv	Additional Ordinary Shares AdditionalOrdinaryShares	344416	shares
CY2021Q1	enlv	Public Share PublicShare	20
CY2021Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	2296107	shares
CY2021Q1	enlv	Public Share PublicShare	18.6
CY2021Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	268205	shares
CY2021Q1	enlv	Public Share PublicShare	18.6
CY2021Q1	enlv	Sales Agent Commission Percentage SalesAgentCommissionPercentage	0.07	pure
CY2021Q1	enlv	Gross Proceeds In Percentage GrossProceedsInPercentage	0.01	pure
CY2021Q1	enlv	Warrants To Purchase WarrantsToPurchase	179501	shares
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	126000	usd
CY2021Q1	us-gaap	Partners Capital Account Public Sale Of Units Net Of Offering Costs PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts	47023000	usd
CY2023	enlv	Expire Grant Year ExpireGrantYear	P10Y
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	986005	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	6.46
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	529082	shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	8.69
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	601227	shares
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	5.93
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	53192	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.53
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	860492	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.49
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	345500	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	12.14
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	384203	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	7.35
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	370839	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	7.14
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	385798	shares
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	7.39
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	58491	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	7.16
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	32730	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	6.43
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	31847	shares
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	6.75
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	596503	shares
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	5.53
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	986005	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	6.46
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	529082	shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	8.69
CY2023	enlv	Weighted Average Fair Value At Grant Date Options Granted WeightedAverageFairValueAtGrantDateOptionsGranted	3.53	pure
CY2022	enlv	Weighted Average Fair Value At Grant Date Options Granted WeightedAverageFairValueAtGrantDateOptionsGranted	5.49	pure
CY2021	enlv	Weighted Average Fair Value At Grant Date Options Granted WeightedAverageFairValueAtGrantDateOptionsGranted	6.23	pure
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2842496	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2245993	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1951000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2712000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2914000	usd
CY2023	enlv	Israeli Corporate Tax Rate IsraeliCorporateTaxRate	0.23	pure
CY2019Q1	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	40000000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1700000	usd
CY2023	enlv	Effective Income Tax Rate Reconciliations At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate	0.23	pure
CY2022	enlv	Effective Income Tax Rate Reconciliations At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate	0.23	pure
CY2021	enlv	Effective Income Tax Rate Reconciliations At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRate	0.23	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.01	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.07	pure
CY2023	enlv	Effective Income Tax Rate Reconciliation Exchange Rate Differencesin Dollars EffectiveIncomeTaxRateReconciliationExchangeRateDifferencesinDollars	-0.05	pure
CY2022	enlv	Effective Income Tax Rate Reconciliation Exchange Rate Differencesin Dollars EffectiveIncomeTaxRateReconciliationExchangeRateDifferencesinDollars	-0.03	pure
CY2021	enlv	Effective Income Tax Rate Reconciliation Exchange Rate Differencesin Dollars EffectiveIncomeTaxRateReconciliationExchangeRateDifferencesinDollars	0.10	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.19	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.20	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.40	pure
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	1605000	usd
CY2021	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	1029000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	205000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	213000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1813000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1365000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	4016000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	3486000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	159000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	185000	usd
CY2023Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	710000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15356000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	23693000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	22259000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	28942000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	22259000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	28942000	usd
CY2022	enlv	Share Based Compensation Allocated To Research And Development Expenses ShareBasedCompensationAllocatedToResearchAndDevelopmentExpenses	876000	usd
CY2021	enlv	Share Based Compensation Allocated To Research And Development Expenses ShareBasedCompensationAllocatedToResearchAndDevelopmentExpenses	1210000	usd
CY2023	enlv	Depreciation Allocated To Research And Development Expense DepreciationAllocatedToResearchAndDevelopmentExpense	802000	usd
CY2022	enlv	Depreciation Allocated To Research And Development Expense DepreciationAllocatedToResearchAndDevelopmentExpense	740000	usd
CY2021	enlv	Depreciation Allocated To Research And Development Expense DepreciationAllocatedToResearchAndDevelopmentExpense	546000	usd
CY2023	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	911000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	813000	usd
CY2023Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	26507000	usd
CY2023Q4	us-gaap	Other Assets Fair Value Disclosure OtherAssetsFairValueDisclosure	413000	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	27733000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	49945000	usd
CY2022Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	299000	usd
CY2022Q4	us-gaap	Other Assets Fair Value Disclosure OtherAssetsFairValueDisclosure	412000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	50656000	usd
CY2023	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	-4244000	usd
CY2023	enlv	Payroll And Related Expenses PayrollAndRelatedExpenses	5265000	usd
CY2022	enlv	Payroll And Related Expenses PayrollAndRelatedExpenses	6371000	usd
CY2021	enlv	Payroll And Related Expenses PayrollAndRelatedExpenses	5054000	usd
CY2023	enlv	Research And Development Services ResearchAndDevelopmentServices	9853000	usd
CY2022	enlv	Research And Development Services ResearchAndDevelopmentServices	8264000	usd
CY2021	enlv	Research And Development Services ResearchAndDevelopmentServices	4557000	usd
CY2023	enlv	Materials Expense MaterialsExpense	1880000	usd
CY2022	enlv	Materials Expense MaterialsExpense	2044000	usd
CY2021	enlv	Materials Expense MaterialsExpense	1505000	usd
CY2023	enlv	Share Based Compensation Allocated To Research And Development Expenses ShareBasedCompensationAllocatedToResearchAndDevelopmentExpenses	524000	usd
CY2023	enlv	Total Research And Development Expense Before Rebate From Israel Innovation Authority TotalResearchAndDevelopmentExpenseBeforeRebateFromIsraelInnovationAuthority	19235000	usd
CY2022	enlv	Total Research And Development Expense Before Rebate From Israel Innovation Authority TotalResearchAndDevelopmentExpenseBeforeRebateFromIsraelInnovationAuthority	19900000	usd
CY2021	enlv	Total Research And Development Expense Before Rebate From Israel Innovation Authority TotalResearchAndDevelopmentExpenseBeforeRebateFromIsraelInnovationAuthority	13901000	usd
CY2023	enlv	Reimbursements From Israel Innovation Authority Participation In Research And Development Costs And Royalties Payable ReimbursementsFromIsraelInnovationAuthorityParticipationInResearchAndDevelopmentCostsAndRoyaltiesPayable	223000	usd
CY2022	enlv	Reimbursements From Israel Innovation Authority Participation In Research And Development Costs And Royalties Payable ReimbursementsFromIsraelInnovationAuthorityParticipationInResearchAndDevelopmentCostsAndRoyaltiesPayable	1207000	usd
CY2021	enlv	Reimbursements From Israel Innovation Authority Participation In Research And Development Costs And Royalties Payable ReimbursementsFromIsraelInnovationAuthorityParticipationInResearchAndDevelopmentCostsAndRoyaltiesPayable	1020000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19012000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18693000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12881000	usd
CY2023	us-gaap	Labor And Related Expense LaborAndRelatedExpense	912000	usd
CY2022	us-gaap	Labor And Related Expense LaborAndRelatedExpense	1289000	usd
CY2021	us-gaap	Labor And Related Expense LaborAndRelatedExpense	1138000	usd
CY2023	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	887000	usd
CY2022	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	681000	usd
CY2021	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	1168000	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	969000	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	1294000	usd
CY2021	us-gaap	Professional Fees ProfessionalFees	1080000	usd
CY2023	enlv	Office Maintenance And Office Expenses OfficeMaintenanceAndOfficeExpenses	906000	usd
CY2022	enlv	Office Maintenance And Office Expenses OfficeMaintenanceAndOfficeExpenses	402000	usd
CY2021	enlv	Office Maintenance And Office Expenses OfficeMaintenanceAndOfficeExpenses	167000	usd
CY2023	us-gaap	General Insurance Expense GeneralInsuranceExpense	567000	usd
CY2022	us-gaap	General Insurance Expense GeneralInsuranceExpense	895000	usd
CY2021	us-gaap	General Insurance Expense GeneralInsuranceExpense	783000	usd
CY2023	enlv	Share Based Compensation Allocated To General And Administrative Expenses ShareBasedCompensationAllocatedToGeneralAndAdministrativeExpenses	1427000	usd
CY2022	enlv	Share Based Compensation Allocated To General And Administrative Expenses ShareBasedCompensationAllocatedToGeneralAndAdministrativeExpenses	1836000	usd
CY2021	enlv	Share Based Compensation Allocated To General And Administrative Expenses ShareBasedCompensationAllocatedToGeneralAndAdministrativeExpenses	1704000	usd
CY2023	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	471000	usd
CY2022	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	707000	usd
CY2021	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	367000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6139000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7104000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6407000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	1565000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	835000	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	120000	usd
CY2022	enlv	Loss Income Related To Marketable Securities LossIncomeRelatedToMarketableSecurities	-1983000	usd
CY2021	enlv	Loss Income Related To Marketable Securities LossIncomeRelatedToMarketableSecurities	5590000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-1224000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-4101000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-562000	usd
CY2023	enlv	Bank Commissions And Other Expenses BankCommissionsAndOtherExpenses	14000	usd
CY2022	enlv	Bank Commissions And Other Expenses BankCommissionsAndOtherExpenses	14000	usd
CY2021	enlv	Bank Commissions And Other Expenses BankCommissionsAndOtherExpenses	328000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	327000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5263000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4820000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent		usd
CY2022Q4	enlv	Liability Held For Sale Current LiabilityHeldForSaleCurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021	us-gaap	Revenues Revenues		usd
CY2022	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets		usd
CY2021	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets		usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent		usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent		usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent		usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent		usd
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.81
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.56
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.69
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17859713	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18394886	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18574484	shares
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2022	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets		usd
CY2021	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets		usd
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities		usd
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities		usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments		usd
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities		usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities		usd
CY2022	enlv	Proceeds From Issuance Of Shares And Warrants Net ProceedsFromIssuanceOfSharesAndWarrantsNet		usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents		usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents		usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022	enlv	Weighted Average Number Of Shares Issued For Cash WeightedAverageNumberOfSharesIssuedForCash		shares
CY2023	enlv	Weighted Average Number Of Stock Options Exercisedin Shares WeightedAverageNumberOfStockOptionsExercisedinShares		shares
CY2021	enlv	Weighted Average Number Of Restricted Stock Units Vested WeightedAverageNumberOfRestrictedStockUnitsVested		shares
CY2023	enlv	Weighted Average Number Of Warrants Exercised WeightedAverageNumberOfWarrantsExercised		shares
CY2022	enlv	Weighted Average Number Of Warrants Exercised WeightedAverageNumberOfWarrantsExercised		shares
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.81
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.56
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.69
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue		usd
CY2022Q4	enlv	Assets Classified As Held For Sale AssetsClassifiedAsHeldForSale		usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.enlivextherapeuticsltd.com/20231231#LiabilityHeldForSaleCurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://www.enlivextherapeuticsltd.com/20231231#LiabilityHeldForSaleCurrent
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue		usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense		pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2022Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2023	enlv	Loss Income Related To Marketable Securities LossIncomeRelatedToMarketableSecurities		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001596812

Files In Submission

Name	View Source	Status
0001213900-24-037878-index-headers.html	Edgar Link	pending
0001213900-24-037878-index.html	Edgar Link	pending
0001213900-24-037878.txt	Edgar Link	pending
0001213900-24-037878-xbrl.zip	Edgar Link	pending
ea0204570-20f_enlivex.htm	Edgar Link	pending
ea020457001ex1-1_enlivex.htm	Edgar Link	pending
ea020457001ex12-1_enlivex.htm	Edgar Link	pending
ea020457001ex12-2_enlivex.htm	Edgar Link	pending
ea020457001ex13-1_enlivex.htm	Edgar Link	pending
ea020457001ex13-2_enlivex.htm	Edgar Link	pending
ea020457001ex15-1_enlivex.htm	Edgar Link	pending
ea020457001ex2-1_enlivex.htm	Edgar Link	pending
ea020457001ex4-18_enlivex.htm	Edgar Link	pending
ea020457001ex8-1_enlivex.htm	Edgar Link	pending
ea020457001ex97-1_enlivex.htm	Edgar Link	pending
enlv-20231231.xsd	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
fin_001.jpg	Edgar Link	pending
fin_002.jpg	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
image_011.jpg	Edgar Link	pending
image_012.jpg	Edgar Link	pending
image_013.jpg	Edgar Link	pending
image_014.jpg	Edgar Link	pending
enlv-20231231_def.xml	Edgar Link	unprocessable
enlv-20231231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ea0204570-20f_enlivex_htm.xml	Edgar Link	completed
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
enlv-20231231_cal.xml	Edgar Link	unprocessable
enlv-20231231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ENLV
Enlivex Therapeutics Ltd. Stock $enlv

2023 Q4 Form 20-F Financial Statement

#000121390024037878 Filed on April 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENLV Enlivex Therapeutics Ltd. Stock $enlv

2023 Q4 Form 20-F Financial Statement

#000121390024037878 Filed on April 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENLV
Enlivex Therapeutics Ltd. Stock $enlv